Verywell Health on MSN8d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
FiercePharma19h
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
WebMD25d
FDA Approves New Treatment for Advanced Breast Cancer
21, 2025 -- The FDA has approved a new treatment for ... with metastatic breast cancer survive more than 5 years, highlighting the urgent need for improved tumor-targeted therapies.
Scientists propose CDK2 enzyme as new target for cancer therapy
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...
Nature5d
FDA approves TROP2-targeted antibody–drug conjugate for breast cancer
The FDA in January approved ... receptor 2 (HER2)-negative breast cancer following endocrine-based therapy and chemotherapy. It is the second TROP2-targeted antibody–drug conjugate (ADC) to ...
HealthDay on MSN11d
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...
Hartford Business3d
FDA approves CT drugmaker’s therapy for rare cancer tumors
Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...
FiercePharma2d
Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
The American Journal of Managed Care15d
FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility
FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...
News Medical on MSN5d
Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...
Targeted Oncology6d
The Targeted Pulse: The FDA Grants MB-105 ODD, and AI Helps Distinguish HER2 0 From 1+ in Breast Cancer
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.